
SPRC
Healthcare · Biotechnology · $869,843 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Apr 24, 2025 | Time not confirmed | — | -6.20 | — |
| Nov 4, 2024 | Time not confirmed | — | -1.70 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.70 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.70 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -1.50 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -1.50 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -14.00 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -14.00 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -17.91 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -17.91 | — |
| May 15, 2019 | Time not confirmed | — | -0.01 | — |
| Nov 28, 2018 | Time not confirmed | — | -0.01 | — |
| Sep 30, 2018 | Time not confirmed | 0.00 | -38.95 | — |
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and…
| After the close |
| 0.00 |
| -0.01 |
| — |
| Mar 31, 2018 | Time not confirmed | 0.00 | -28.00 | — |